- Home
- CMMB vs AWH Comparison
CMMB vs AWH Comparison
Compare CMMB & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- AWH
- Stock Information
- Founded
- CMMB 2004
- AWH 1993
- Country
- CMMB Israel
- AWH United States
- Employees
- CMMB N/A
- AWH N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- AWH Medical/Dental Instruments
- Sector
- CMMB Health Care
- AWH Health Care
- Exchange
- CMMB Nasdaq
- AWH Nasdaq
- Market Cap
- CMMB 15.8M
- AWH 13.5M
- IPO Year
- CMMB N/A
- AWH N/A
- Fundamental
- Price
- CMMB $1.29
- AWH $0.80
- Analyst Decision
- CMMB Strong Buy
- AWH Buy
- Analyst Count
- CMMB 3
- AWH 2
- Target Price
- CMMB $5.67
- AWH $4.40
- AVG Volume (30 Days)
- CMMB 214.5K
- AWH 58.9K
- Earning Date
- CMMB 11-07-2024
- AWH 11-11-2024
- Dividend Yield
- CMMB N/A
- AWH N/A
- EPS Growth
- CMMB N/A
- AWH N/A
- EPS
- CMMB N/A
- AWH N/A
- Revenue
- CMMB N/A
- AWH $8,923,000.00
- Revenue This Year
- CMMB N/A
- AWH $15.59
- Revenue Next Year
- CMMB N/A
- AWH $108.47
- P/E Ratio
- CMMB N/A
- AWH N/A
- Revenue Growth
- CMMB N/A
- AWH N/A
- 52 Week Low
- CMMB $0.42
- AWH $0.74
- 52 Week High
- CMMB $2.55
- AWH $6.01
- Technical
- Relative Strength Index (RSI)
- CMMB 33.68
- AWH 38.68
- Support Level
- CMMB $1.29
- AWH $0.76
- Resistance Level
- CMMB $1.59
- AWH $0.89
- Average True Range (ATR)
- CMMB 0.17
- AWH 0.07
- MACD
- CMMB -0.05
- AWH 0.01
- Stochastic Oscillator
- CMMB 2.00
- AWH 40.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.